Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lucitanib - Advenchen Laboratories/Shanghai Institute of Materia Medica

Drug Profile

Lucitanib - Advenchen Laboratories/Shanghai Institute of Materia Medica

Alternative Names: AL 3810; CO-3810; E-3810 - Ethical Oncology Science; S-80881; S-80881-2

Latest Information Update: 14 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Advenchen Laboratories; Shanghai Institute of Materia Medica
  • Developer Clovis Oncology; HaiHe Biopharma; Servier; Shanghai Institute of Materia Medica
  • Class Acetamides; Antineoplastics; Cyclopropanes; Naphthalenes; Phenyl ethers; Quinolines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Antioxidants; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein c-kit inhibitors; Proto oncogene proteins c raf inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Discontinued Breast cancer; Non-small cell lung cancer

Most Recent Events

  • 26 Dec 2018 Servier discontinues the phase II trial prematurely in Breast Cancer due to inefficacy and safety results
  • 19 Oct 2018 Efficacy and adverse events data from the phase II FINESSE trial in Breast cancer presented at the 43rd European Society for Medical Oncology Congress (ESMO-2018)
  • 01 Aug 2018 Clovis Oncology receives notice for return of rights for Lucitanib in World (excluding China) from Servier
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top